INTRODUCTION
============

Lipemia is defined as visible turbidity in serum or plasma samples due to the presence of lipoprotein particles, especially chylomicrons. The most common cause of turbidity is a high concentration of triglycerides \[[@B1][@B2]\]. Lipemia can be a significant source of analytical errors in clinical laboratory settings, which may result in serious diagnostic consequences. It is the most common interference in outpatient populations, occurring in up to 7% of samples \[[@B3]\].

The most common pre-analytical cause of lipemia is usually non-compliance to fasting prior to sampling \[[@B4]\]. Further, some pathological conditions may increase the turbidity of samples because of an increase in the concentration of triglycerides; these include alcohol abuse, diabetes mellitus, hypothyroidism, pancreatitis, and certain treatments, including protease inhibitors (in HIV infection), estrogens, and contraceptives \[[@B5][@B6]\].

Lipemia interferes with measurements of biological parameters (sodium ion, transaminases, etc.) by changing the dispersion or absorption of light and even producing volume depletion in the aqueous phase, increasing the non-aqueous volume instead \[[@B7]\]. The turbidity produced by high lipids in samples mainly affects spectrophotometric methods due to the decrease in intensity of light reaching the solution \[[@B4][@B8]\]. One example of the solvent displacement effect is pseudohyponatremia, a well-recognized effect resulting from sodium remaining in the aqueous phase of the sample \[[@B9]\].

In clinical laboratory settings, it is important to remove lipemia by using an appropriate method. Sample ultracentrifugation is the recommended method according to the CLSI \[[@B10]\]. However, because of high cost, the necessary equipment is not available in many laboratories. Therefore, less potent centrifugation methods to remove lipoproteins and eliminate turbidity have been studied. Studies have reported no statistically significant differences in the serum concentrations of sodium ion, creatinine, urate, proteins, lactate dehydrogenase, and magnesium in lipemic serum after high-speed centrifugation at 10,000×*g* or ultracentrifugation at 100,000×*g* \[[@B8][@B9]\]. Accordingly, it is important to determine if there are other easier methods to remove lipemia in common laboratory samples.

In addition to centrifugation methods, there are chemical methods for lipemia removal. For example, polar solvents can be used to separate lipids from the aqueous phase in lipemic samples based on phase differences. One of these methods uses the commercial product LipoClear (StatSpin, Norwood, Massachusetts, USA), which contains a non-ionic, non-toxic polymer that binds to the lipids, and after centrifugation, the concentration of biochemicals in the supernatant can be measured. However, LipoClear interferes with the measurement of several biochemical parameters, including gamma-glutamyl transferase, C-reactive protein, and creatine kinase 2 \[[@B11][@B12]\]. Another product used for lipemia removal is 1,1,2-trichlorotrifluoroethane. This chlorofluorocarbon is used as an organic solvent with polar properties, which allows the separation of lipids by liquid-liquid phase extraction.

We investigated whether lipemia in serum/plasma samples can be removed using a method that is easier and more practicable than ultracentrifugation, focusing on high-speed centrifugation and liquid-liquid extraction using either LipoClear or 1,1,2-trichlorotrifluoroethane. Our study is novel in that it evaluated the interference of chemical processes during lipemia removal for measuring biochemical parameters in plasma/serum samples, using high-speed centrifugation as a reference method. We assessed the suitability of chemical methods that do not require the use of a high-speed centrifuge in the laboratory.

METHODS
=======

1. Study design and biochemical analyses
----------------------------------------

This was a prospective and transversal study involving seven hospital laboratories in Spain: Gran Canaria Dr. Negrín University Hospital (Las Palmas de Gran Canaria), Bellvitge University Hospital (Barcelona), Corporació Sanitària Parc Taulí (Barcelona), Cruces University Hospital (Vizcaya), Virgen del Rocío University Hospital (Sevilla), Albacete Hospital (Albacete), and Miguel Servet University Hospital (Zaragoza). Gran Canaria Dr. Negrín University Hospital participated in phase 1 of the study. A minimum of 36 lipemic samples from the other six laboratories were planned to be included from January 2013 to January 2014.

Samples were randomly selected from those processed routinely in each laboratory over the study period. They were obtained from patients who visited the hospitals for scheduled analysis. No extra clinical procedures other than the scheduled ones were performed. Biochemical parameters were measured in ISO 9001-certified laboratories that followed Westgard quality control rules (calibration procedures were performed when required). Institutional Review Board approval was obtained at each hospital.

### 1) Phase 1: Comparison of ultracentrifugation and high-speed centrifugation

In this phase, lipemic samples were processed in the clinical laboratory of the Gran Canaria Dr. Negrín University Hospital by ultracentrifugation and by high-speed centrifugation, followed by biochemical analyses. Thirty-two lipemic serum samples randomly selected from patients who had undergone a blood test in the laboratory were included. The triglyceride concentration of these samples was between 900 and 4,300 mg/dL. The samples were processed on the day of collection or were stored at 2--8℃ for less than one week in case they could not be processed immediately. Serum samples were homogenized with a vortex mixer (Thermolyne, Dubuque, Iowa, USA); 1.5 mL and 1 mL were separated for the ultracentrifugation and high-speed centrifugation methods, respectively.

For ultracentrifugation, the 1.5-mL sample was pipetted into a 13×51-mm polycarbonate tube and centrifuged in a Beckman TL-100 ultracentrifuge at 108,200×*g* for 20 minutes at 6℃ (Beckman Instruments, Fullerton, California, USA), using a fixed-angle TLA 100.3 rotor. After ultracentrifugation, the infranatant was collected using a fine-needle syringe.

For high-speed centrifugation, the 1-mL sample was centrifuged at 10,000×*g* for 10 minutes in a high-speed centrifuge (Abbott Heraeus Biofuge, Willowbrook, Illinois, USA). The aqueous phase was collected at the bottom of the tube, using a fine-needle syringe with care not to aspirate the non-aqueous phase.

Concentrations of the following biochemical parameters were measured using a Cobas c701 analyzer (Roche Diagnostics, Mannheim, Germany): triglycerides by the lipoprotein-lipase/oxidase/peroxidase method; sodium ion, potassium ion, and chloride ion by indirect potentiometry; glucose by the hexokinase method; total protein by the Biuret method; albumin by binding of cromocresol green; creatinine by the Jaffe method; urea by the urease method; alkaline phosphatase, gamma-glutamyl transferase, alanine aminotransferase, and aspartate-aminotransferase by methods recommended by the International Federation of Clinical Chemistry (IFCC) \[[@B13][@B14][@B15][@B16]\]; calcium by the o-cresolphthalein complexone method; and bilirubin by the 3,5-dichlorophenyl diazonium method.

### 2) Phase 2: Comparison of three methods of lipemia removal.

The other six participating laboratories tested a minimum of 12 samples with triglyceride concentrations \<750 mg/dL (8.55 mmol/L), 12 samples with triglyceride concentrations of 750--1,500 mg/dL (8.55--17.1 mmol/L), and 12 samples with triglyceride concentrations \>1,500 mg/dL (17.1 mmol/L). The samples were processed on the day of collection or were stored at 2--8℃ for less than one week in case they could not be processed immediately. Serum or plasma samples were homogenized.

The following lipid removal methods were used in this phase: (1) high-speed centrifugation: 1 mL of serum/plasma sample in an Eppendorf tube was centrifuged for 15 minutes at 10,000×*g*. The lower aqueous phase was collected using a fine-needle syringe, being careful not to aspirate the lipid phase. (2) (StatSpin, Norwood, Massachusetts, USA): in an Eppendorf tube, 0.5 mL of sample and 0.1 mL of the LipoClear reagent were added, left to stand for 10 minutes, and mixed well. The mixture was centrifuged at 2,000×*g* for 20 minutes, and the clarified supernatant was collected for analysis. All results were multiplied by 1.2 to compensate for the dilution of the original sample, according to the manufacturer\'s instruction. (3) 1,1,2-trichlorotrifluoroethane (Merck, Darmstadt, Germany): in a glass tube, 1 mL of sample and 0.7 mL of 1,1,2-trichlorotrifluoroethane were added, homogenized vigorously for 30 seconds on a shaker to ensure complete homogenization, and centrifuged for 10 minutes at 2,000×*g*. The supernatant was collected for analysis.

In total, 14 biochemical parameters were studied (and concentration of triglycerides in serum/plasma was determined to verify that they were lipemic samples). All parameters were frequently requested in the clinical laboratories participating in the study. The presence of chylomicrons (sodium and potassium ions) is known to interfere with the measurement of certain selected parameters (sodium ion, transaminases, etc.). Concentrations of the biochemical parameters were measured using the same methods as in Phase 1, on one of the following systems: AU5400 (Olympus, Tokyo, Japan), Cobas c711 (Roche Diagnostics), Cobas c701 (Roche Diagnostics), or ADVIA 2400 (Siemens, Munich, Germany).

2. Statistical analysis
-----------------------

Grubbs test was used to detect aberrant results. The Kolmogorov-Smirnov test was used to analyze data distribution. Parametric and non-parametric data were summarized as means with standard deviations or medians with interquartile range, and compared using the paired t-test or Wilcoxon test, respectively (significance threshold: *P*\<0.05). Statistical analyses were performed using SPSS version 17.0 (Armonk, New York, USA).

For phase 1, differences in the mean or median obtained from ultracentrifugation and high-speed centrifugation were analyzed to determine if the limit for clinically significant interference (LCSI) was exceeded.

The LCSI was calculated according to the formula recommended by the Sociedad Española de Bioquímica Clínica y Patología Molecular \[[@B17]\]:

LCSI=(CV*bi* / 2) • (X*c* / 100),

where CV*bi* is the coefficient of intra-individual biological variation obtained from CLSI \[[@B18]\] and X*c* is the critical or clinical decision concentration of the parameter.

For phase 2, we analyzed means or medians of biochemical parameters from high-speed centrifugation and LipoClear and from high-speed centrifugation and 1,1,2-trichlorotrifluoroethane, to determine if differences exceeded the LCSI.

RESULTS
=======

[Table 1](#T1){ref-type="table"} shows the results obtained in phase 1. Data for all biochemical parameters were normally distributed. Statistically significant differences were found between ultracentrifugation and high-speed centrifugation for five parameters, but the differences in the means did not exceed the LCSI.

[Table 2](#T2){ref-type="table"} shows the phase 2 results. Owing to missing results, 110--160 samples could be processed successfully. Differences in the following biochemical parameters did not exceed the LCSI in either comparison: sodium ion, potassium ion, chloride ion, glucose, creatinine, urea, alkaline phosphatase, gamma-glutamyl transferase, bilirubin, and alanine aminotransferase. Differences exceeded the LCSI for protein, calcium, and aspartate aminotransferase in the comparison of high-speed centrifugation and 1,1,2-trichlorotrifluoroethane. Differences exceeded the LCSI for protein, albumin, and calcium in the comparison of high-speed centrifugation and LipoClear.

DISCUSSION
==========

We investigated whether a method that is easier and more practicable than ultracentrifugation can be used to remove lipemia in serum/plasma samples. A large number of biochemical parameters were tested, and the methods most commonly used for lipemia removal in laboratories were compared.

We found no statistically significant differences between ultracentrifugation and high-speed centrifugation for potassium ion, protein, albumin, creatinine, urea, alkaline phosphatase, calcium, gamma-glutamyl transferase, and aspartate aminotransferase. Sodium ion, chloride ion, glucose, bilirubin, and alanine-aminotransferase showed statistically significant differences, but none of these exceeded the LCSI. Thus, the current reference method, ultracentrifugation, can be replaced with high-speed centrifugation at 10,000×*g* for 15 minutes. Analysis of the lowest fraction at the bottom would be suitable for measuring the concentrations of the biochemical parameters included in this study.

High-speed centrifugation is easy to perform in the laboratory, even in the emergency laboratory, where lipemic samples often arrive. It does not involve the introduction of any reagent that may interfere with the measurements, and only requires a high-speed centrifuge that reaches 10,000×*g*. In accordance with our findings, Dimeski and Jones \[[@B9]\] reported no significant differences between ultracentrifugation and high-speed centrifugation, using metrological criteria based on the coefficient of variation of data for sodium ion, creatinine, urate, protein, lactate dehydrogenase, and magnesium.

We found differences in protein, calcium, and aspartate aminotransferase in the comparison of high-speed centrifugationa and 1,1,2-trichlorotrifluoroethane, and in protein, albumin, and calcium in the comparison of high-speed centrifugation and LipoClear. LipoClear and 1,1,2-trichlorotrifluoroethane were both not suitable for lipemia removal in serum/plasma samples when testing for protein and calcium. This may be because of incomplete removal of the interference by these reagents. The use of lipemia removal methods other than centrifugation-based methods may involve the introduction of a reagent that might interfere with the measurement of certain biochemical parameters. Our results do not support the use of LipoClear, in agreement with those of Saracevic et al \[[@B12]\], who concluded that LipoClear is not suitable for lipemia removal from samples to measure concentrations of glucose, sodium ion, potassium ion, chloride ion, phosphorus, magnesium, creatine kinase MB, alkaline phosphatase, gamma-glutamyl transferase, protein, albumin, and C-reactive protein. In addition, 1,1,2-trichlorotrifluoroethane has been found to interfere with the measurement of certain biochemical parameters, including gamma-glutamyl transferase, C-reactive protein, and creatine kinase MB \[[@B11][@B12]\]. In our study, 1,1,2-trichlorotrifluoroethane did not interfere with glutamyl transferase measurements.

Thus, high-speed centrifugation at 10,000 ×*g* for 15 minutes is appropriate for lipemia removal in serum/plasma samples. LipoClear and 1,1,2-trichlorotrifluoroethane are not suitable because they interfere with the measurement of certain biochemical parameters.
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###### Comparison between ultracentrifugation and high-speed centrifugation for removing lipemia in serum/plasma samples (N=32)

![](alm-38-518-i001)

  Biochemical parameter                         Mean (SD) Ultracentrifugation   Mean (SD) High-speed centrifugation   *P*^\*^   LCSI
  --------------------------------------------- ------------------------------- ------------------------------------- --------- -------
  Sodium ion; c.sust. (mmol/L)                  141.52 (4.59)                   141.03 (4.88)                         \< 0.05   1.27
  Potassium ion; c.sust. (mmol/L)               4.66 (0.64)                     4.98 (0.68)                           0.52      0.34
  Chloride ion; c.sust. (mmol/L)                102.63 (4.96)                   102.31 (5.17)                         \< 0.05   0.61
  Glucose; c.sust. (mmol/L)                     10.00 (5.13)                    9.93 (5.05)                           \< 0.05   0.28
  Protein; c.mass (g/L)                         73.58 (4.33)                    73.22 (4.49)                          0.09      0.99
  Albumin; c.mass (g/L)                         44.00 (1.60)                    43.75 (1.67)                          0.35      0.68
  Creatinine; c.sust. (µmol/L)                  77.26 (21.48)                   76.93 (21.57)                         0.22      1.77
  Urea; c.sust. (mmol/L)                        35.53 (13.19)                   35.41 (13.03)                         0.40      3.97
  Alkaline phosphatase; c.cat. (µkat/L)         1.46 (0.36)                     1.46 (0.36)                           0.16      0.048
  Gamma-glutamyl transferase; c.cat. (µkat/L)   1.44 (1.49)                     1.43 (1.50)                           0.08      0.988
  Calcium; c.sust. (mmol/L)                     2.41 (0.11)                     2.41 (0.11)                           0.94      0.09
  Bilirubin; c.sust. (µmol/L)                   4.96 (2.37)                     4.59 (2.21)                           \< 0.05   0.684
  Alanine-aminotransferase; c.cat. (µkat/L)     0.61 (0.32)                     0.59 (0.30)                           \< 0.05   0.073
  Aspartate-aminotransferase; c.cat. (µkat/L)   0.47 (0.24)                     0.47 (0.24)                           0.38      0.028

^\*^This value was calculated using a paired t-test.

Abbreviations: LCSI, limit for clinically significant interference; c.sust., concentration of substance; c.cat., catalytic concentration.

###### Comparison between liquid-liquid lipemia removal methods (LipoClear and 1,1,2-trichlorotrifluoroethane) and high-speed centrifugation for removing lipemia in serum/plasma samples

![](alm-38-518-i002)

  Biochemical parameter                         LipoClear          1,1,2-trichlorotrifluoroethane                                                        
  --------------------------------------------- ------------------ -------------------------------- --------- ----- -------------------- ----- --------- -----
  Sodium ion; c.sust. (mmol/L)                  140.40 (29.40)     122                              \< 0.05   NO    133.09 (15.31)^\*^   130   0.07      NO
  Potassium ion; c.sust. (mmol/L)               4.55 (0.74)^\*^    120                              \< 0.05   NO    4.87 (0.64)^\*^      135   0.82      NO
  Chloride ion; c.sust. (mmol/L)                99.82 (24.41)      153                              \< 0.05   NO    103.95 (7.88)        156   \< 0.05   NO
  Glucose; c.sust. (mmol/L)                     6.80 (5.72)        156                              \< 0.05   NO    6.83 (6.00)          160   \< 0.05   NO
  Protein; c.mass (g/L)                         65.39 (9.45)^\*^   156                              \< 0.05   YES   73.31 (6.30)^\*^     160   \< 0.05   YES
  Albumin; c.mass (g/L)                         43.30 (6.53)^\*^   122                              \< 0.05   YES   43.35 (4.91)^\*^     126   \< 0.05   NO
  Creatinine; c.sust. (µmol/L)                  79.29 (36.24)      157                              \< 0.05   NO    84.86 (35.36)        160   0.150     NO
  Urea; c.sust. (mmol/L)                        37.78 (19.08)      157                              0.07      NO    38.00 (16.80)        161   \< 0.05   NO
  Alkaline phosphatase; c.cat. (µkat/L)         1.42 (0.69)        121                              0.05      NO    1.42 (0.72)          122   \< 0.05   NO
  Gamma-glutamyl transferase; c.cat. (µkat/L)   1.27 (1.28)        112                              \< 0.05   NO    1.32 (1.5)           110   0.57      NO
  Calcium; c.sust. (mmol/L)                     2.22 (0.66)        143                              \< 0.05   YES   2.38 (0.34)          142   \< 0.05   YES
  Bilirubin; c.sust. (µmol/L)                   4.96 (3.42)        143                              \< 0.05   NO    4.45 (3.59)          155   \< 0.05   NO
  Alanine-aminotransferase; c.cat. (µkat/L)     0.43 (0.33)        157                              \< 0.05   NO    0.53 (0.39)          161   \< 0.05   NO
  Aspartate-aminotransferase; c.cat. (µkat/L)   0.42 (0.29)        155                              \< 0.05   NO    0.48 (0.37)          160   \< 0.05   YES

^\*^This value followed a parametric distribution.

^†^This value was calculated using a paired t-test or Wilcoxon test.

Abbreviations: IQR, interquartile range; LCSI, limits for clinically significant interference; c.sust., concentration of substance; c.cat., catalytic concentration.
